Becton Dickinson and Company (BDX)vsTalen Energy Corporation (TLN)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
TLN
Talen Energy Corporation
$328.29
+3.96%
UTILITIES · Cap: $14.51B
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 735% more annual revenue ($21.92B vs $2.63B). BDX leads profitability with a 8.0% profit margin vs -8.3%. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
TLN
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Intrinsic value data unavailable for TLN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 58.0% year-over-year
Earnings expanding 34.5% YoY
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Trading at 13.7x book value
ROE of -17.7% — below average capital efficiency
Currently unprofitable
Operating margin of -36.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : TLN
The strongest argument for TLN centers on Revenue Growth, EPS Growth. Revenue growth of 58.0% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : TLN
The primary concerns for TLN are Price/Book, Return on Equity, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while TLN is a hypergrowth play — different risk/reward profiles.
TLN carries more volatility with a beta of 1.61 — expect wider price swings.
TLN is growing revenue faster at 58.0% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 42/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?